GlaxoSmithKline News

's stock had its "neutral" rating restated by equities researchers at Bryan Garnier & Cie in a research report issued on Wednesday, Analyst Ratings.Net reports.

GlaxoSmithKline has today received an offer for its thrombosis brands and Notre-Dame de Bondeville site from Aspen Global Incorporated and Aspen Pharmacare Holdings Limited.

Canadian Solar Inc. shares spiked 7.66 percent to close at $10.12 a share Monday.

Aspen Pharmacare said it would acquire the Arixtra and Fraxiparine/Fraxodi brands of thrombosis drug from GlaxoSmithKline, except in China, Pakistan and India.

UBS AG's price target suggests a potential upside of 4.42% from the stock's previous close.

British pharma GlaxoSmithKline is still looking into "misrepresentations" in data from its research and development labs in China- misrepresentations that led to the halt of an experimental drug for multiple sclerosis.

Oil firms led U.K. stocks higher after a broker upgrade on Monday, while shares of GlaxoSmithKline PLC also showed upbeat moves after a target price lift.

Anh is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.

To see what our analysts have discovered about these stocks read the InvestorsObserver's PriceWatch Alerts at http://www.investorsobserver.com/pr/61320130 Today's PriceWatch Alerts cover the following stocks: Anheuser-Busch InBev , GlaxoSmithKline , Capital One , Safeway , and Onyx Pharmaceuticals .

After three years of restrictions, advisers to the Food and Drug Administration decided that the diabetes drug rosiglitazone, marketed by GlaxoSmithKline as Avandia, is safe after all, and does not cause undue risk of heart attacks.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! For the second time this month, GlaxoSmithKline is embroiled in scandal in China.

The North Carolina Chamber is holding its annual summit on manufacturing, where business officials will discuss reform and other issues.

Drug manufacturer GlaxoSmithKline said Thursday it has investigated an accusation that its salespeople in China bribed doctors and found no evidence of wrongdoing.

's stock had its "buy" rating reaffirmed by TheStreet in a research note issued on Wednesday, Stock Ratings Network reports.

BRITISH drugmaker GlaxoSmithKline PLC says it dismissed one employee and a second has resigned in the wake of a scandal over misrepresented data in a research paper published in 2010.

GlaxoSmithKline has finally won a green light from Britain's healthcare cost agency NICE for its platelet-boosting drug Revolade, after offering a price discount to the country's state-run healthcare service.

British drugmaker GlaxoSmithKline PLC says it dismissed one employee and a second has resigned in the wake of a scandal over misrepresented data in a research paper published in 2010.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! After conducting an internal investigation, GlaxoSmithKline has determined that a scientific paper that was published in Nature Medicine contained fabricated data and has dismissed Jingwu Zang, one of the listed authors, who was a senior vp and head of R&D in ... (more)

's stock had its "buy" rating restated by stock analysts at Societe Generale in a report issued on Tuesday, Stock Ratings Network.com reports.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Get ready for a trick question.